Aldatu Biosciences Revenue and Competitors

Boston, MA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Aldatu Biosciences's estimated annual revenue is currently $2M per year.(i)
  • Aldatu Biosciences's estimated revenue per employee is $155,000

Employee Data

  • Aldatu Biosciences has 13 Employees.(i)
  • Aldatu Biosciences grew their employee count by 8% last year.

Aldatu Biosciences's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
VP DevelopmentReveal Email/Phone
3
VP OperationsReveal Email/Phone
4
Co-Founder and Chief Science OfficerReveal Email/Phone
5
Research AssociateReveal Email/Phone
6
Quality, Regulatory and Manufacturing Co-opReveal Email/Phone
7
Technology SpecialistReveal Email/Phone
8
Research AssociateReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Aldatu Biosciences?

Aldatu Biosciences advances the development of innovative diagnostic tools that drive our collective response to global health emergencies. Aldatu's proprietary PANDAA technology is a qPCR-enabling platform that overcomes long-standing diagnostic challenges to enhance the quality and affordability of high-throughput infectious disease diagnostics and improve patient access to diagnostics in resource-limited countries. Our PANDAA qDx™ SARS-CoV-2 assay is being implemented in numerous clinical labs and we have established Aldatu Diagnostics, a clinical lab dedicated to supporting our community's needs for COVID-19 testing using Aldatu Biosciences' PANDAA technology.

keywords:N/A

N/A

Total Funding

13

Number of Employees

$2M

Revenue (est)

8%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2M1386%N/A
#2
$1.2M14-44%N/A
#3
$4M16-43%N/A
#4
$2.3M16-6%N/A
#5
$2.2M176%N/A